Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire

Background: Elexacaftor–tezacaftor–ivacaftor (ETI) is a novel, highly effective CFTR modulator combination proven to enhance lung function and body weight in people with cystic fibrosis (pwCF) carrying a F508del mutation. Recently, we revealed significant reductions in abdominal symptoms (AS) in Ger...

Descripción completa

Detalles Bibliográficos
Autores principales: Mainz, Jochen G., Barucha, Anton, Huang, Pu, Bechinger, Lilith, Duckstein, Franziska, Polte, Louise, Sadrieh, Pauline, Nährlich, Lutz, Eickmeier, Olaf, Van Dullemen, Suzanne, Eschenhagen, Patience, Schwarz, Carsten, Lüth, Stefan, Zagoya, Carlos, Graepler-Mainka, Ute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658783/
https://www.ncbi.nlm.nih.gov/pubmed/38026920
http://dx.doi.org/10.3389/fphar.2023.1167407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658783/
https://www.ncbi.nlm.nih.gov/pubmed/38026920
http://dx.doi.org/10.3389/fphar.2023.1167407

Ejemplares similares